作者
Huanyu Gong,Yong Cheng,Qiang Li,Yong He,Qijun Cai,Yongjin Tang,Yulong Liu,Lu Kuang,Yingxin Li,Jingjie Shang,Chengzhi Li,Kangshou Liu,Mingrong Cao,Lu Wang,Xueying Ling,Hao Xu
摘要
This study aimed to evaluate the diagnostic value of 18 F-FAPI-04 PET/CT in unresectable hepatocellular carcinoma(uHCC) and with a comparative analysis against 18 F-FDG PET/CT. Patients with uHCC who underwent paired 18 F-FDG and 18 F-FAPI-04 PET/CT for pre-treatment staging or post-treatment restaging were retrospectively included. The two tracers were compared in terms of their ability to detect intrahepatic and extrahepatic lesions, including sensitivity, maximum standardized uptake value (SUV max ), and tumour-to-background ratio (TBR). Eighty-five patients (mean age: 53.9 ± 10.0 years) were included. In patient-based analysis, 18 F-FAPI-04 showed higher intrahepatic lesion detection sensitivity (98.8% vs. 85.9%, P = 0.003) and lesion uptake than 18 F-FDG (median maximum SUV max :9.1 vs. 7.6, P = 0.028). Contrast enhanced CT/MRI(CECT/MR) demonstrated comparable sensitivity to 18 F-FAPI-04 PET and superior to 18 F-FDG PET (96.5% vs. 85.9%, P = 0.004). In lesion-based analysis, 18 F-FAPI-04 demonstrated significantly higher sensitivity (89.5% vs. 57.1%, P < 0.001), intrahepatic lesion SUV max, (median:6.5 vs. 3.7, P < 0.001) and TBR (median:3.4 vs. 1.7, P < 0.001) than 18 F-FDG, but lower sensitivity than CECT/MR (89.5% vs. 96.2%, P < 0.001). Among organ transplant recipients, 18 F-FDG showed superior sensitivity to 18 F-FAPI-04 for detecting intrahepatic lesions (87.5% vs. 37.5%, P = 0.002). 18 F-FDG had a higher detection rate of portal vein tumour thrombosis (PVTT) (95.7% vs. 43.5%, P = 0.002), lymph node metastasis (95.7% vs. 82.8%, P = 0.004), and lung metastasis (69.3% vs. 58.4%, P = 0.007). 18 F-FAPI-04 was significantly better than 18 F-FDG in detecting peritoneal metastasis (100% vs. 69.6%, P = 0.016). According to 18 F-FAPI-04 PET/CT, Barcelona Clinic Liver Cancer (BCLC) and China Liver Cancer (CNLC) staging were changed in 16 (18.8%) and 22 (25.9%) patients, respectively. 18 F-FAPI-04 exhibits significant diagnostic advantages in uHCC patients, particularly in the detection of intrahepatic lesions, peritoneal metastases, and better contrast compared with 18 F-FDG. Among organ transplant recipients, 18 F-FDG may offer higher sensitivity than 18 F-FAPI-04 for intrahepatic lesion detection. 18 F-FDG outperforms 18 F-FAPI-04 in identifying PVTT. The rational selection of these two tracers may improve the accuracy of clinical staging.